Lymphoma Clinical Trials | Norton Healthcare Louisville, Ky.

Lymphoma Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Active lymphoma trials at Norton Cancer Institute include:

B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (017006)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Classical Hodgkin Lymphoma (cHL)

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

Classical Hodgkin Lymphoma (cHL)

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Diffuse Large B-cell Lymphoma (DLBCL)

A Randomized Phase 3 Study to Evaluate the efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1. (ENGINE Study)

Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Diffuse Large B-cell Lymphoma (DLBCL)

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL

Follicular Lymphoma

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Follicular Lymphoma

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma

Hodgkin Lymphoma

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology

Hodgkin Lymphoma

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Lymphoma

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Lymphoma

A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB(PRT062070) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL or T-CELL NON-HODGKIN LYMPHOMA (NHL)

Lymphoma

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Lymphoma

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.

Lymphoma

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Mantle Cell Lymphoma (MCL)

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Non-Hodgkin’s Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma

Small Cell Lung Cancer (SCLC)

A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the treatment of adult patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC), and Follicular Lymphoma (FL)

T-Cell Lymphoma

Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory […]

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3501

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

New joints allow teen cancer survivor to walk again

It was prom, and Trinity Goodson felt like a princess. The Pekin, Indiana, junior spent the day perfecting her nails, makeup, and hair. After she posed for pictures, she headed to the car for a […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped [...]

Read Full Story

Norton cancer specialist’s research paves way for new FDA-approved lymphoma treatment

The U.S. Food and Drug Administration recently approved a new cancer drug that has been available only to patients enrolled by a Norton Cancer Institute physician and one other researcher nationwide. Don A. Stevens, M.D., [...]

Read Full Story
Related Stories

Cutaneous lymphoma: Blood cancer that starts in the skin

Why does a blood cancer start in the skin? Lymphomas are cancers of the immune system, which generally arise in lymph nodes and other lymphatic tissue.  The immune system consists of white blood cells, the […]

Read Full Story

New joints allow teen cancer survivor to walk again

It was prom, and Trinity Goodson felt like a princess. The Pekin, Indiana, junior spent the day perfecting her nails, makeup, and hair. After she posed for pictures, she headed to the car for a […]

Read Full Story

Cancer-free patient finds hope from clinical trial

When Brenda Montgomery enrolled in a clinical trial at Norton Cancer Institute in February 2016, she hoped the new drug being researched would trounce the cancer she had battled for nine years. She also hoped [...]

Read Full Story

Norton cancer specialist’s research paves way for new FDA-approved lymphoma treatment

The U.S. Food and Drug Administration recently approved a new cancer drug that has been available only to patients enrolled by a Norton Cancer Institute physician and one other researcher nationwide. Don A. Stevens, M.D., [...]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.